Radia Research is an independent translational drug-discovery organization operating as a virtual biotech. We retain scientific, program, and IP control while engaging specialist chemistry, biochemistry, microbiology, ADME, structural biology, and later PK/PD partners as programs mature.
Our public portfolio is intentionally concise. Each program is organized around a bounded development question, a defined empirical gate, and a path to specialist execution.
Discovery of chemically orthogonal LpxH inhibitor series designed to support Gram-negative entry, experimental validation, and medicinal-chemistry expansion.
A structurally guided research program centered on the essential bacterial lipid-II flippase MurJ.
A mechanistic program focused on advanced MASH and hepatic fibrosis, with emphasis on hepatic stellate-cell biology and collagen production and trafficking.
Radia is built to move quickly without pretending every capability must live inside one organization. The core team defines the scientific thesis, gates, evidence standards, and IP strategy; specialist partners execute the work best suited to them.
We are interested in research relationships that materially advance a defined program: assay execution, medicinal chemistry, microbiology, structural biology, developability, or translational planning. The best first conversation is concrete—what can be tested, by whom, under what evidence standard, and what decision the result should unlock.
For the LpxH program, the immediate experimental objective is a small, diverse, rapidly purchasable compound basket tested in the same cycle for purified LpxH activity and wild-type E. coli/K. pneumoniae MIC. That paired result is designed to distinguish target engagement, entry/efflux limitation, off-target antibacterial activity, and true negatives efficiently.
Founder & Research Lead, Radia Research. For scientific collaboration, assay execution, chemistry, microbiology, funding partnerships, or program-development discussions, use the organization email below.